The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
暂无分享,去创建一个
D. Esseltine | P. Sonneveld | P. Richardson | A. Boral | T. Facon | J. Harousseau | J. Bladé | M. Schuster | L. Rosiñol | D. Irwin | E. Stadtmauer | S. Rajkumar | M. Coleman | R. Niesvizky | K. Anderson